All In Biotech

Drug Trial Radar · NCT01771458

A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer

A Randomized Proof-of-concept Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer.

Last checked: Nov 19, 2026Latest source record: Nov 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 742 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

742

Actual

Start

Oct 2012

Primary completion

Oct 2016

Study completion Dec 2016

Sponsor

Lead sponsor
Institut CurieAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 18, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

SHIVA is a proof of concept randomized phase II trial which compares two treatment strategies for patients with refractory cancer. From a tumor biopsy, a molecular profile of the disease is established (mutations, amplifications, hormone receptor status). If a molecular abnormality is identified for which an approved targeted agent is available, patients are randomized randomized between two arms: * Targeted therapy based on the molecular profile * Conventional therapy based on investigator's choice. A cross-over is proposed at disease progression.

Conditions

  • Reccurent/Metastatic Solid Tumor Disease

Interventions

  • Targeted therapy based on molecular profiling : ImatinibDrug

  • Tumor biopsyProcedure

  • Standard ChemotherapyDrug

  • Targeted therapy based on molecular profiling : EverolimusDrug

  • Targeted therapy based on molecular profiling : VemurafenibDrug

  • Targeted therapy based on molecular profiling : SorafenibDrug

  • Targeted therapy based on molecular profiling : ErlotinibDrug

  • Targeted therapy based on molecular profiling : Lapatinib + TrastuzumabDrug

  • Targeted therapy based on molecular profiling : DasatinibDrug

  • Targeted therapy based on molecular profiling : Tamoxifen (or letrozole if contra-indication)Drug

  • Targeted therapy based on molecular profiling : AbirateroneDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Patient's progression free survival (according RECIST 1.1) of targeted therapy based on molecular profiling versus conventional chemotherapy.

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Centre régional de lutte contre le cancer de Bourgogne Georges François Leclerc

    Dijon, France

  • Centre Leon Berard

    Lyon, France

  • Institut Paoli Calmettes

    Marseille, France

  • Insitut Curie

    Paris, France

  • Institut Curie Hopital Rene Huguenin

    Saint-Cloud, France

  • Institut de cancérologie de l'Ouest Centre René Gauducheau

    Saint-Herblain, France

  • Institut Claudius Régaud

    Toulouse, France

  • Centre Alexis Vautrin

    Vandœuvre-lès-Nancy, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.